Evolva appoints Norbert Bender as Chief Medical Officer

Reinach, Switzerland, 2 May 2011 - Evolva Holding SA (SIX: EVE) announces today that it has appointed Norbert Bender, M.D, Ph.D., an experienced drug development professional, as its Chief Medical Officer (CMO) with immediate effect.

Norbert Bender is an M.D. from the University of Frankfurt, Germany and has a Ph.D. in Biochemistry and Pharmacy from the same institution. He practiced for 10 years as a medical doctor in internal medicine at the Frankfurt University Hospital. He subsequently worked for more than 20 years in various senior functions in pharmaceutical (Hoechst, Knoll) and biotech companies (Cardion, Trigen, ViroLogik), in both Europe and North America. Dr. Bender has particular expertise in the cardiovascular space and has been involved in the successful development of Ramipril and its fixed combinations, Reviparine, Sibutramine and Adalimumab.

He will take the CMO post that has been vacant since the departure of Jessica Mann in 2010 and will be a member of the Group Management Team. He has been working as a medical consultant to Evolva since October 2010.

Neil Goldsmith, Managing Director and CEO of Evolva commented, “I welcome Norbert to our management team and look forward to his contribution to the progress of our programmes. Norbert has extensive experience both as a drug developer and as a practicing doctor. This will be of great value as our compounds progress along their development paths.”

About Evolva

Evolva is an international, innovative synthetic biology company with a world-class research platform. Evolva strives to improve people’s lives by applying its technology and other resources to the discovery and development of new products and processes that benefit the health, well-being and financial economy of patients, consumers and partner companies around the world. Evolva uses biosynthetic and evolutionary technologies to artificially create and optimise small molecule compounds and their production routes. Our approach differs from that of the mainstream in the pharmaceutical and chemical industries. We have discovery partnerships ongoing both in pharma and in nutrition. In addition we have a pipeline of promising compounds aimed at infectious and cardio-renal
indications.

For more information visit www.evolva.com.

Contact Details

Evolva

Neil Goldsmith, CEO                  Jakob Dynnes Hansen,                     CFO Paul Verbraeken, IR
neilg@evolva.com                      jakobdh@evolva.com                          paulv@evolva.com
+ 41 61 485 2005                       + 41 61 485 2034                                 + 41 61 485 2035
 

Capital MSL

Mary Clark, Justine Lamond and Hollie Vile evolva@capitalmsl.com +44 (0)20 7307 5337

This press release contains specific forward-looking statements, e.g. statements including terms like believe, assume, expect or similar expressions. Such forward-looking statements are subject to known and unknown risks, uncertainties and other factors which may result in a substantial divergence between the actual results, financial situation, development or performance of the company and those explicitly or implicitly presumed in these statements. Against the background of these uncertainties readers should not place undue reliance on forward-looking statements. The company assumes no responsibility to update forward-looking
statements or to adapt them to future events or developments.